-
Product Insights
Polycystic Ovarian Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. The main risk factor for polycystic ovary syndrome (PCOS) is a family history. Other factors include type 2 diabetes and heart disease. The Polycystic ovarian syndrome pipeline market research report provides a comprehensive overview on the therapeutics under development for Polycystic ovary syndrome, complete with analysis by stage of...
-
Product Insights
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Disease – Global Clinical Trials Review, H1 2019
GlobalData's clinical trial report, “Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Global Clinical Trials Review, H1, 2019" provides an overview of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) clinical trials scenario. This report provides top line data relating to the clinical trials on Congenital Adrenal Hyperplasia (Adrenogenital Syndrome). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Sector Analysis
Use of Telemedicine in the United States of America (USA) during the COVID-19 Pandemic
Prior to the COVID-19 pandemic, telemedicine had not reached its full potential in the US, with several barriers preventing its widespread uptake, including reimbursement and access issues, lack of awareness, resistance to change, preference for in-person care, and technical and connectivity issues. It is widely anticipated that COVID-19 may be the tipping point for telemedicine as the full potential of the technology is increasingly realized by patients, healthcare systems, and payers. As a result of the pandemic, regulations and policies...